Conjugados Anticuerpo Fármaco contra el estroma tumoral: El principio del fin? por Mirella Zulueta, Business Development Director en Oncomatryx The potential of a technology trigger Despite many research breakthroughs over the last few decades, conventional cancer treatment strategies still face many limitations. Antibody-drug conjugates (ADCs) belong to a fairly new class of targeted … Leer más
Contra el cáncer desde el stroma: nueva via para el cáncer de páncreas Por Laureano Simon, CEO de Oncomatryx Pancreatic cancer is the fourth most fatal cancer in men and women. Most patients with pancreatic cancer progress to either metastatic or locally advanced disease in the asymptomatic phase. Its prognosis has not improved over the … Leer más
El «tumor microenvironment»: Un elemento clave al que disparar Novel precision drugs that target the tumor microenvironment are entering the battlefield against cancer. Recent advances in the prevention and treatment of early stages of cancer have achieved significant success. However, little progress has been made in the development of new methods to fight late and invasive stages … Leer más
